These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19032914)

  • 1. Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: evidence from clinical trials.
    Moukarbel GV; Solomon SD
    Curr Heart Fail Rep; 2008 Dec; 5(4):197-203. PubMed ID: 19032914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
    Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M; Solomon SD
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: what have we learned from recent clinical trials?
    Mielniczuk L; Stevenson LW
    Curr Opin Cardiol; 2005 Jul; 20(4):250-5. PubMed ID: 15956818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE inhibitors in heart failure: what more do we need to know?
    Demers C; Mody A; Teo KK; McKelvie RS
    Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
    Bissessor N; White H
    Vasc Health Risk Manag; 2007; 3(4):425-30. PubMed ID: 17969373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the setting of acute myocardial infarction.
    Salam AM
    Expert Opin Investig Drugs; 2003 Mar; 12(3):501-7. PubMed ID: 12605571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The renin-angiotensin system: the role of inhibitors, blockers, and genetic polymorphisms in the treatment and prevention of heart failure.
    Hebert PR; Foody JM; Hennekens CH
    Curr Vasc Pharmacol; 2003 Mar; 1(1):33-9. PubMed ID: 15320851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have similar effects in the improvement of left ventricular dysfunction after myocardial infarction in Japanese?
    Miura S; Saku K
    Intern Med; 2009; 48(22):1929-30. PubMed ID: 19915291
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence of and risk factors for severe acute kidney injury in children with heart failure treated with renin-angiotensin system inhibitors.
    Terano C; Ishikura K; Miura M; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Ando T; Honda M
    Eur J Pediatr; 2016 May; 175(5):631-7. PubMed ID: 26687571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
    Azizi M; Ménard J
    Circulation; 2004 Jun; 109(21):2492-9. PubMed ID: 15173039
    [No Abstract]   [Full Text] [Related]  

  • 15. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
    Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valsartan in the treatment of heart attack survivors.
    Jugdutt BI
    Vasc Health Risk Manag; 2006; 2(2):125-38. PubMed ID: 17319456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From black and white to shades of gray: race and renin-angiotensin system blockade.
    Havranek EP
    J Am Coll Cardiol; 2008 May; 51(19):1872-3. PubMed ID: 18466802
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-angiotensin system.
    Guo X; Saini HK; Wang J; Gupta SK; Goyal RK; Dhalla NS
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):717-32. PubMed ID: 16076281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction.
    LeJemtel TH; Hochman JS; Sonnenblick EH
    J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):47S-51S. PubMed ID: 7775715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.